Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck & Co

Showing 15 posts of 53 posts found.

Merck and Roche extend Victrelis co-promotion deal to Europe

July 22, 2011
Sales and Marketing Merck & Co, Roche, Victrelis, hepatitis C

Merck & Co is ramping up efforts to push its new hepatitis C treatment Victrelis to the fore, signing a …

News
Merck & Co

Merck to close one facility, boosts another

July 5, 2011
Manufacturing and Production, Research and Development Ireland, Merck & Co, pharma job cuts, pharma manufacturing news

Merck & Co continues to shake up its network of facilities, deciding to close a recently-acquired site in the USA …

News
Merck & Co

Merck to develop biosimilar of Pfizer’s Enbrel

June 15, 2011
Research and Development, Sales and Marketing Enbrel, Merck & Co, biosimilar

Merck & Co is to develop its own version of Pfizer’s ageing arthritis drug Enbrel with a South Korean manufacturer. …

News

Merck redesigns drug labels for clarity

June 14, 2011
Manufacturing and Production FDA, Labelling, Merck & Co

The FDA has approved a major overhaul of labelling for a range of Merck & Co products, paving the way …

News

Merck plans cancer drug submissions later this year

June 7, 2011
Research and Development, Sales and Marketing Merck & Co, ridaforolimus

Merck & Co is to submit its oral investigational cancer drug ridaforolimus to European and US regulators later this year …

News

GSK and Merck cut vaccine prices

June 6, 2011
Sales and Marketing Bill and Melinda Gates Foundation, GSK, Merck & Co, developing world, vaccines

GlaxoSmithKline and Merck & Co have pledged to offer their rotavirus vaccines at discounted prices to developing countries. GSK is …

News
Merck & Co's Victrelis (boceprevir)

Merck’s hepatitis drug Victrelis approved by FDA

May 16, 2011
Sales and Marketing Merck & Co, Victrelis, boceprevir, hepatitis C

The FDA has approved Merck’s hepatitis C drug Victrelis, the first oral treatment for the disease. Victrelis (boceprevir) has been …

News

Merck & Co kicks off expansion of Durham vaccines facility

April 26, 2011
Manufacturing and Production Merck & Co, manufacturing and production, vaccines

Merck & Co is expanding its vaccines facility in North Carolina, USA, bucking a recent trend at the manufacturer for …

News
Arthritis drug Remicade

J&J and Merck reach compromise on arthritis drug rights

April 19, 2011
Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi

Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …

News
Merck & Co workers protest job cuts

Merck says sale of Oss facility would be too expensive

March 8, 2011
Manufacturing and Production, Research and Development Holland, Merck & Co, Oss, Oss pharma research, Pantarhei Bioscience

The debate around the closure of Merck & Co’s R&D and manufacturing unit in Oss, the Netherlands, rumbles on, with …

News

Fujifilm buys into bio with Merck acquisitions

March 2, 2011
Manufacturing and Production Biomanufacturing, Fujifilm, Merck, Merck & Co, Merck/MSD Biomanufacturing Network, contract manufacturing

Japanese photography and imaging company Fujifilm continued its diversification into other sectors with the acquisition of the Merck/MSD Biomanufacturing Network, …

News

Sale of Organon facility in Oss may avert closure

February 15, 2011
Manufacturing and Production Merck & Co, Netherlands, Oss

The fate of an Organon manufacturing and R&D facility in the Netherlands, currently under threat of closure by parent company …

News

Merck dipped into the red as 2010 ended

February 4, 2011
Sales and Marketing 2010 pharma results, Merck & Co

Merck & Co made a $531 million loss in the final quarter of 2010 – down from a profit of …

News

Bio and clinical plants feature in 2011 FOYA honours

January 25, 2011
Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing

Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …

News

Merck suffers late-stage blow to vorapaxar

January 18, 2011
Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar

An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026